Prevnar 13 is a pneumococcal 13-valent conjugate vaccine approved by the FDA in December 2011. It protects against 13 strains of Streptococcus pneumoniae, a greater number than the original Prevnar vaccine. Prevnar 13 is recommended for infants and children from 6 weeks of age to prevent pneumococcal pneumonia, otitis media, and invasive disease. It is administered as a 4-dose series in infants and children, with doses given at 2, 4, 6 and 15-18 months of age.

1. Prevnar 13™
Pneumococcal 13-valent
conjugate vaccine
Manufacturer: Wyeth
FDA Approval Date: 12/2011

2. Prevnar 13™
- Pneumococcal 13-valent conjugate
Clinical Application
• Indications:
• Immunization of infants and children against Strep
pneumoniae caused by included serotypes
• Immunization of infants and children against otitis
media caused by Strep pneumoniae serotypes 4, 6B,
9V, 14, 18C, 19F, and 23F
• Immunization of adults ≥50 years against
pneumococcal pneumonia and invasive disease
caused by included Strep pneumoniae serotypes

3. Prevnar 13™
- Pneumococcal 13-valent conjugate
Clinical Application
• Place in therapy:
• Vaccination used to immunize patients as young
as 6 weeks against various strains of Strep
pneumoniae

4. Prevnar 13™
- Pneumococcal 13-valent conjugate
Clinical Application
• Contraindications:
• Hypersensitivity
• Warnings:
• Apnea and Acute Illness
• Precautions:
• Use in pts w/ altered immunocompetence
• Use in Elderly (>65yoa)

5. Prevnar 13™
- Pneumococcal 13-valent conjugate
Clinical Application
• Pregnancy:
• B
• Lactation:
• Excretion in breast milk unknown/use caution

6. Prevnar 13™
- Pneumococcal 13-valent conjugate
Drug Facts
• Pharmacology
• Administered as a series of 4 injections
given at 2, 4, 6, and 15-18 months of age
• Full efficacy w/in 1 month of the final
vaccination

7. Prevnar 13™
- Pneumococcal 13-valent conjugate
Drug Interactions
• Drug Interactions – Precipitant Drugs
• Belimumab: May ↓the therapeutic effect of
this Vaccine (inactivate)
• Fingolimod: May ↓the therapeutic effect of
this Vaccine (inactivate)

8. Prevnar 13™
- Pneumococcal 13-valent conjugate
Adverse Effects
• Common Adverse Effects: (>10%)
• Central nervous system: Chills, drowsiness,
fatigue, fever, headache, insomnia, irritability
• Dermatologic: Rash
• Gastrointestinal: Appetite decreased
• Local: Erythema, limitation of arm motion,
pain, swelling, tenderness
• Neuromuscular & skeletal: Arthralgia, myalgia

9. Prevnar 13™
- Pneumococcal 13-valent conjugate
Monitoring Parameters
• Efficacy Monitoring
• None
• Toxicity Monitoring
• None

10. Prevnar 13™
- Pneumococcal 13-valent conjugate
Prescription Information
• Dosing:
• Infants and Children 6 weeks-59 months: 0.5 mL/dose X
4 doses:
• The first dose may be given as young as 6 weeks - 2 months.
• The 3 remaining doses are usually given at 4, 6, and 12-15 months
• The recommended dosing interval is 4-8 weeks
• The minimum interval between doses in children <1 year of age is 1
month
• The minimum interval between the third and fourth dose is 2 months
• Cost: Estimated $430 for complete series

11. Prevnar 13™
- Pneumococcal 13-valent conjugate vaccine
Summary
• Prevnar 13™ is the successor to the previously-marketed
Prevnar® and is used in patients as young as 6 weeks.
• Prevnar 13™ contains an additional 6 serotypes
of Streptococcus pneumoniae, compared to the 7 serotypes
provided in the original Prevnar®
formulation.
• The CDC has announced that young children appear to be at
increased risk of febrile seizures when given the pneumococcal
conjugate vaccine (PCV 13) at the same time as the inactivated
influenza virus vaccine (TIV). The risk appears to be greatest
from ages 12-23 months. Because febrile seizures are typically
benign and occur in 2% to 5% of all young children, the ACIP
does not recommend a delay in administration of either vaccine
or altering the vaccine schedule in any manner due to the
potential risk of infection.

12. Prevnar 13™
- Pneumococcal 13-valent conjugate
References
1. Prenvar-13 package insert. Wyerth
Pharmaceuticals. Jan. 2012.
http://labeling.pfizer.com/showlabeling.aspx?id=501
2. Pubmed. MMWR Recomm Rep. 2010 Dec
10;59(RR-11):1-18. Accessed 01/12.
http://www.ncbi.nlm.nih.gov/pubmed/21150868